Extract
We congratulate the authors of the highly anticipated European Respiratory Society (ERS) clinical practice guidelines on treatment of sarcoidosis [1]. The ERS clinical practice guidelines are an update of the guideline developed by the American Thoracic Society, ERS and World Association of Sarcoidosis and Other Granulomatous Disorders in 1999. The current task force committee has put more emphasis on patient tailored choice than the 1999 guideline. They used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology to develop 12 specific treatment recommendations for management of sarcoidosis. All recommendations were based on very low to low quality of evidence. As such, an important message of the 2021 guideline is that high or even moderate quality evidence for optimal management of sarcoidosis is lacking [2].
Abstract
A perspective on the recently published ERS clinical practice guideline on treatment of sarcoidosis: although knowledge of the pathogenesis of sarcoidosis has improved, this has not yet translated into better evidence-based therapies https://bit.ly/3qaBIpg
Footnotes
Conflict of interest: M.S. Wijsenbeek reports grants from Dutch Lung foundation for sarcoidosis research, and grants from Boehringer Ingelheim; consulting fees and lecture honoraria from Boehringer Ingelheim and Hoffmann la Roche; outside the submitted work. J.R. Miedema reports consulting fees and lecture honoraria from Boehringer Ingelheim; lecture honoraria from Roche; outside the submitted work. All other authors have nothing to disclose.
- Received December 8, 2021.
- Accepted December 12, 2021.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org